ACLXHIGH SIGNALFINANCIAL10-K

ACLX experienced severe financial deterioration with net losses more than doubling to $228.9M while revenue collapsed 79% from $107.9M to $22.3M.

This represents a fundamental shift from a company with substantial revenue generation to one burning cash at an accelerated rate with minimal income. The combination of massive revenue decline and doubled losses suggests either loss of a major partnership/licensing deal or significant changes in their business model that have eliminated near-term revenue streams.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

ACLX's financial position deteriorated dramatically across all key metrics, with operating cash flow burn increasing 152% to $210.3M while revenue collapsed from $107.9M to just $22.3M, resulting in net losses more than doubling to $228.9M. Despite reduced capital expenditures of $2.3M (down 83%), the company's cash position declined to $80.3M from $105.7M, while total assets contracted 15% to $604.0M. The sharp revenue decline combined with accelerated cash burn signals a critical inflection point that raises serious questions about the sustainability of current operations and funding runway.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-151.9%
-$83.5M-$210.3M

Operating cash flow fell 151.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-113.3%
-$107.3M-$228.9M

Net income declined 113.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-84%
-$137.6M-$253.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Capital Expenditure
Cash Flow
-82.7%
$13.4M$2.3M

Capex reduced 82.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
-79.4%
$107.9M$22.3M

Revenue declined 79.4% — significant demand weakness or market share loss warrants investigation.

Cash & Equivalents
Balance Sheet
-24.1%
$105.7M$80.3M

Cash decreased 24.1% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-22.9%
$599.3M$462.2M

Current assets declined 22.9% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-21.4%
$256.5M$201.6M

Liabilities reduced 21.4% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-16.9%
$125.4M$104.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-15.1%
$711.3M$604.0M

Total assets contracted 15.1% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
Overview We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.
Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constrained to existing biologic structures, which has limited their impact and opportunity.
Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional CAR-Ts.
Our lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel or anito-cel (formerly, CART-ddBCMA), which is currently being evaluated in our pivotal Phase 2 iMMagine-1, Phase 3 iMMagine-3, and Phase 2 GEM-AnitoFIRST trials in patients with multiple myeloma (MM).
In 2024, we completed dosing in our pivotal Phase 2 clinical trial (iMMagine-1) of anito-cel in patients with fourth line or later relapsed or refractory MM (rrMM).
+7 more — sign up free →
REMOVED
Overview We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Although cell therapies have shown benefits to date, cell therapies have primarily been constrained to existing biologic structures, which has limited their impact and opportunity.
Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Our lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel or anito-cel (formerly, CART-ddBCMA), which is currently being evaluated in our pivotal Phase 2 iMMagine-1 and the Phase 3 iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM).
We received FDA clearance of an IND application and have initiated a Phase 1 trial in generalized myasthenia gravis (gMG) in 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →